JV Diabetes Public Health Analytics Hub

Turning Diabetes Data
Into Action

A focused portfolio dedicated to diabetes analytics — exploring research, charts, and public health storytelling that make patterns in prevalence, A1C control, amputations, dialysis, and disparities easier to understand across New York State and New York City.

Prevalence A1C Control Amputations Dialysis Disparities

👥

1.5M+

New Yorkers living with diabetes

🧪

>9%

A1C poor control statewide

🏥

100K+

Diabetes-related hospital discharges

💉

8K+

New Yorkers on dialysis

All 5 NYC Boroughs covered

2024 SPARCS inpatient data

26K+ Discharge records analyzed

🌲 Why This Hub?

Diabetes disproportionately affects New York City's underserved communities — yet the data telling that story often sits buried in raw government files. This hub transforms those datasets into clear, actionable visualizations that anyone can explore.

Built as a healthcare analytics portfolio project combining skills in data cleaning, public health interpretation, dashboard design, and geospatial analysis.

🌱 Key Focus Areas

🩸 Diabetes Prevalence by Race/Ethnicity
🧪 A1C Control (>9% as poor control indicator)
🦵 Diabetes-Related Amputations
💉 Dialysis & Kidney Disease Links
🏥 Hospital Utilization Patterns (SPARCS)
📍 Neighborhood-Level Disparities
🗺️ Borough Comparisons — All 5 NYC Boroughs

📊

Diabetes Analytics Dashboard

SPARCS 2024 Summary

New York State
Inpatient Data

🌿 Dashboard Slicers

Filter 2024 SPARCS diabetes inpatient data by borough and indicator.

Data source: 2024 SPARCS inpatient discharge records — hospital discharges, costs, ED visits, and length of stay.

26,147

Diabetes Inpatient Discharges — All NYC Boroughs

SPARCS 2024

5.9 days

Average Length of Stay

SPARCS 2024 average

$809.6M

Total Inpatient Costs

SPARCS 2024 total

18,670

Emergency Department Cases

71.4% ED share

Borough

Year

Indicator

📊 Diabetes Inpatient Discharges — All NYC Boroughs (26,147)

📈 2024 Diabetes Discharges by Age Group

🏥 Avg Length of Stay by Borough (days)

🚨 Emergency Department Share % by Borough

🧬 2024 Diabetes Discharges by Race/Ethnicity (Patient Count)

💵 2024 Total Inpatient Charges vs Costs by Borough (Diabetes, NYC)

📋 Borough Comparison Table

Borough	SPARCS Discharges	Avg Length of Stay	Total Costs	ED Cases	ED Share
🏙️ Bronx	5,466	5.9 days	$179.6M	4,416	80.8%
🏘️ Brooklyn	6,303	6.7 days	$209.2M	5,205	82.6%
🌆 Manhattan	7,891	5.6 days	$274.2M	4,378	55.5%
🌏 Queens	4,991	5.6 days	$112.3M	3,611	72.4%
🌳 Staten Island	1,496	5.5 days	$34.4M	1,060	70.9%

📰

Research Articles

Peer-Reviewed Studies

Diabetes / Public Health

💉

2022 : Renal disease in patients with type 2 diabetes: Magnitude of the problem, risk factors and preventive strategies

Summary

Chronic kidney disease affects an estimated 27% of Type 2 diabetes patients globally — with the highest prevalence in the USA. Key risk factors include uncontrolled A1C, hypertension, proteinuria, obesity, and duration of diabetes. Early-onset Type 2 diabetes carries a 3.58x higher ESRD risk than late-onset. GLP-1 receptor agonists and SGLT-2 inhibitors show significant kidney-protective effects with long-term use.

Open Article Research Page

🗽

2025 : Diabetes and Health Inequities among New York City Adults

Summary

Official NYC DOHMH report (May 2025) documenting diabetes prevalence, blood sugar control, and lower-extremity amputations across all five boroughs. In 2022, 800,000+ NYC adults had diabetes (11.3%). Black (14%), Latino (14%), and Asian/PI (13%) New Yorkers were nearly twice as likely to have diabetes as white (7%) New Yorkers. The Bronx had the highest amputation rate at 74.5 per 100,000. Very high poverty neighborhoods had 3x the amputation rate of low-poverty neighborhoods.

Open Article Research Page

🏥

SPARCS Long/Short Term Complications and Amputations

Summary

Shows SPARCS PQI diabetes indicators for NYC from 2009 to 2023, with focus on short-term complications, long-term complications, and lower-extremity amputations.

Open Article Research Page

🍽️

2024 : Patients with diabetes struggling to afford food and control their HbA1c in food-insecure areas in Bronx, NY

Summary

Explores how food insecurity and neighborhood food access relate to poor A1C control among adults with diabetes in the Bronx.

Open Article Research Page

🦵

2022 : New York State Diabetes-Related Amputation: A Horror Story

Summary

Highlights diabetes-related lower-extremity amputation patterns and why complications prevention matters for public health.

Open Article Research Page

📈

2024 : Diabetes Incidence and Prevalence

Summary

CDC national and state trend report summarizing diabetes incidence, prevalence, mortality burden, and long-term trends across the United States.

Open Article Research Page

🧬

2025 : Epidemiological Patterns of Diabetes Mellitus in The United States of America: An Observational Multicenter Analysis From 1990 to 2024

Summary

Multicenter observational analysis of diabetes incidence and prevalence patterns across the United States from 1990 to 2024, stratified by age, sex, race, and diabetes type.

Open Article Research Page

📟

2025 : Navigating Continuous Glucose Monitoring Adoption: Insights From Hispanic Adults With Insulin-Treated Type 2 Diabetes

Summary

Explores barriers and facilitators to continuous glucose monitoring adoption among Hispanic adults with insulin-treated Type 2 diabetes, including cost, insurance coverage, provider guidance, and lived experience after CGM trial use.

Open Article Research Page

💉

Renal Disease in Type 2 Diabetes — Magnitude, Risk Factors & Prevention

Chronic kidney disease affects an estimated 27% of Type 2 diabetes patients globally — with the highest prevalence in the USA. Key risk factors include uncontrolled A1C, hypertension, proteinuria, obesity, and duration of diabetes. Early-onset Type 2 diabetes carries a 3.58x higher ESRD risk than late-onset. GLP-1 receptor agonists and SGLT-2 inhibitors show significant kidney-protective effects with long-term use.

Diabetic Nephropathy CKD · 27% Prevalence ESRD Prevention SGLT-2 · GLP-1 Protection

Read Study 📖

Source: Renal Disease in Patients with Type 2 Diabetes — ScienceDirect 2022

10.5%

Global diabetes prevalence, 2021

536.6M adults ages 20–79

12.2%

Projected prevalence, 2045

783.2M adults projected

30–40%

T2DM patients who may develop DKD

About one-third overall

2–3×

Higher cardiovascular risk with DKD

GFR loss + albuminuria add risk

📊 Diabetes and DKD Burden

What this means: DKD is not rare. Around one-third of people with diabetes may develop diabetic kidney disease, and type 2 diabetes is the largest driver of ESRD worldwide.

🌎 Global Diabetes Growth, 2021 to 2045

What this means: The diabetes population is projected to grow sharply by 2045, which means more people may need kidney-protection care.

💵 Diabetes Health Expenditure Forecast

What this means: Diabetes care already costs hundreds of billions globally, and kidney complications can add more pressure to health systems.

🛡️ Prevention and Kidney-Protection Signals

What this means: Prevention is the main story. Glycemic control, RAAS blockade, SGLT2 inhibitors, GLP-1 agonists, and finerenone are tools that can help slow DKD progression.

🧬 DKD Clinical Progression Pathway

What this means: DKD can move from hyperfiltration to albuminuria, hypertension, proteinuria, GFR loss, and ESRD. The article stresses that early prevention is better than waiting for late-stage kidney failure.

🗽

Diabetes & Health Inequities Among NYC Adults — EPI Data Brief No. 146

Official NYC DOHMH report (May 2025) documenting diabetes prevalence, blood sugar control, and lower-extremity amputations across all five boroughs. In 2022, 800,000+ NYC adults had diabetes (11.3%). Black (14%), Latino (14%), and Asian/PI (13%) New Yorkers were nearly twice as likely to have diabetes as white (7%) New Yorkers. The Bronx had the highest amputation rate at 74.5 per 100,000. Very high poverty neighborhoods had 3x the amputation rate of low-poverty neighborhoods.

NYC DOHMH · May 2025 800K+ Adults with Diabetes Amputation Disparities Tables 1, 3 & 5

Read Report 📖

Full data breakdown from EPI Data Brief No. 146 · Tables 1, 3 & 5 · NYC DOHMH · May 2025

Key Findings — Tables 1, 3 & 5

794K

NYC Adults with Diabetes

↑ 11.3% of all NYC adults · 2022

15.1%

Bronx Diabetes Prevalence

↑ Highest borough · vs 7.9% Manhattan

16.5%

Bronx A1C >9% (Poor Control)

↑ Highest borough · vs 10.4% Staten Island

3,184

NYC Diabetes Amputations 2022

↑ 43.7 per 100,000 people

74.5

Bronx Amputation Rate

↑ per 100,000 · 2× Manhattan rate

3×

Very High vs Low Poverty Amputation

↑ 81.8 vs 27.1 per 100,000

🔍 Key Finding: Latino and Black New Yorkers have nearly double the diabetes prevalence of white New Yorkers (14.0% and 13.6% vs 7.0%). Males have 3.4× the amputation rate of females (70.5 vs 21 per 100,000). The Bronx has 74.5 amputations per 100,000 — the highest of any borough — driven by the intersection of high diabetes prevalence, poor A1C control, and extreme neighborhood poverty.

🏙️ Chart 1 · Diabetes Prevalence by Borough — 2022 (Table 1)

🧬 Chart 2 · Diabetes Prevalence by Race/Ethnicity — 2022 (Table 1)

💰 Chart 3 · Diabetes Prevalence by Neighborhood Poverty (Table 1)

📅 Chart 4 · Diabetes Prevalence by Age Group (Table 1)

🧪 Chart 5 · A1C Blood Sugar Control by Borough — 2022 (Table 3) · % of patients in each A1C range

🦵 Chart 6 · Amputation Rate by Borough per 100K — 2022 (Table 5)

🧬 Chart 7 · Amputation Rate by Race/Ethnicity per 100K (Table 5)

💰 Chart 8 · Amputation Rate by Neighborhood Poverty (Table 5)

⚧ Chart 9 · Amputation Rate by Sex per 100K (Table 5)

Source: NYC Dept. of Health & Mental Hygiene — Epi Data Brief No. 146, May 2025 · Tables 1, 3 & 5 · Community Health Survey 2022 · NYC A1C Registry 2022 · SPARCS 2022

🍽️

Food Insecurity & Poor A1C Control in the Bronx — Bronx, NY Study

A 2024 peer-reviewed study of 5,500 Bronx Type 2 diabetes patients found that those who reported food insecurity had 59% higher odds of poor glycemic control (A1C ≥ 9%). Critically, the effect held even in food-secure neighborhoods — meaning the individual need, not just the ZIP code, drives the risk. The study population was 43% Hispanic and 30% non-Hispanic Black, reflecting the Bronx's demographics. Uninsured patients had 48% higher odds of poor control than commercially insured patients.

59% Higher Odds of Poor A1C Bronx · 5,500 Patients Food Insecurity · SDOH Open Access · 2024

Read Study 📖

Source: Chambers et al. — Public Health Nutrition, Cambridge University Press · Albert Einstein College of Medicine · 2024

Charts and Data Tables

The related Food Insecurity and Poor A1C Control charts now live inside this article page, so the Research Articles page stays clean and easy to navigate.

📄 Research Article & Data — Food Insecurity

Full data breakdown from Chambers et al. 2024 — Albert Einstein College of Medicine · Bronx, NY

Key Findings — Tables 1, 2 & 3

21.5%

Patients with Poor A1C (≥9%)

↑ 1,183 of 5,500 patients

1.59×

Adjusted Odds — Food Need vs None

↑ aOR 1.59 (CI: 1.26–2.00)*

1.83×

Food Need in Food-Secure Area

↑ Highest risk group (aOR 1.83)

1.48×

Uninsured vs Commercially Insured

↑ aOR 1.48 (CI: 1.12–1.95)*

43.1%

Hispanic Patients in Study

↑ Largest racial/ethnic group

0.41×

Age 65+ Protective Effect

↓ Lower odds of poor control

🔍 Counterintuitive Finding: Patients with food insecurity living in food-SECURE neighborhoods had the HIGHEST odds of poor glycemic control (aOR 1.83) — even higher than those in food-insecure areas (aOR 1.72). Individual food need, not neighborhood food access, is the primary driver.

📊 Chart 1 · Poor A1C by Race/Ethnicity (Table 1)

📊 Chart 2 · Poor A1C by Insurance Type (Table 1)

📊 Chart 3 · Adjusted Odds Ratios — Food Need Groups (Table 3)

📊 Chart 4 · Poor A1C by Age Group (Table 1)

📊 Chart 5 · Bivariate vs Adjusted Odds Ratios (Tables 2 & 3)

📊 Chart 6 · % with Poor A1C by Food Need × Neighborhood (Table 1)

🦵

New York State Diabetes-Related Amputation: A Horror Story

An estimated 50,000 New Yorkers lost limbs to diabetes-related amputations from 2009 to 2021. NY State's 84% increase in amputations from 2009–2017 was nearly double the 47% national increase. NYC alone saw a 92.4% rise — with Queens up 122.5%, Manhattan 113.9%, and the Bronx 96.7%. The 5-year death rate is 29% after minor amputations and 57% after major ones. One above-the-knee amputation costs $200,000+ in the first year alone. A Mississippi county slashed its amputations by 75% with early clinical care. New York State has done none of this.

50,000 Limbs Lost 2009–2021 84% State Increase 92.4% NYC Increase Preventable · Unfunded

Read Report 📖

Source: Health People Special Report — Chris Norwood & Jesse Weiss, MSN, RN · December 2022 · South Bronx

Projected Total49,367 NY amputations,
2009-2021

State Increase84.1% from 2009-2017

NYC Increase92.4% from 2009-2017

Major Amputation57% five-year death rate

📈 Diabetes-Related Amputation Rate Trends — NYC Boroughs + NY State

What this means: The Bronx started high and kept rising, but every borough shows a worsening pattern by 2017. This supports the report's warning that prevention failed across the city.

🏙️ 2009–2017 Increase Comparison

What this means: New York's increase was far above the national increase, and NYC rose even faster than the state overall.

🧮 Documented vs Projected Amputations

What this means: The report estimates that the four missing data years may account for more amputations than the documented 2009–2017 period.

⚠️ Five-Year Death Rate After Amputation

What this means: Amputation is not just a foot problem. The report frames it as a major survival risk, especially after major limb loss.

🦶 Prevention Impact Examples

What this means: The report argues that amputations can be reduced when health systems invest in early foot care, education, and regular wellness visits.

What This Means

These charts turn the article's warning into a clear data story: diabetes-related amputations rose sharply in New York, the Bronx and NYC were hit hard, the missing years may hide even more harm, and prevention can work when health systems act early.

📊 Research Article & Data

Reports backed by real NY State SPARCS PQI data — interactive charts from actual discharge records

📈

SPARCS PQI Data — Diabetes Indicators · NYC 2009–2023

Real NY State hospital inpatient Prevention Quality Indicators · Rates per 100,000 people · All 5 NYC boroughs

Open in SPARCS ↗

52.0

Bronx Amputation Rate 2023

↑ per 100,000 people

25.3

Manhattan Amputation Rate 2023

↑ per 100,000 people

2.1×

Bronx vs Manhattan Gap

↑ Bronx rate more than double

248.1

Bronx Long-Term Complications 2023

↑ per 100,000 people

🦵 Amputation Rate by Borough — 2023

🏙️ All PQI Indicators by Borough — 2023

📅 Bronx Amputation Trend 2009–2023

📈 Amputation Trend All Boroughs 2009–2023

Source: NY State SPARCS De-Identified Adult PQI by County — dataset iqp6-vdi4 · Rates per 100,000 people · 2009–2023

Hispanic Diabetes: Data, Culture, and Care

Research-backed charts and evidence about diabetes patterns, care access, social determinants, and prevention across Hispanic and Latino communities.

Hispanics

Hispanic and Latino communities carry a diverse diabetes burden shaped by culture, family history, neighborhood conditions, food access, income, insurance coverage, language access, and trust in care. This section looks across Hispanic populations while still keeping room for subgroup differences that can be hidden when all communities are treated as one single category.

Hispanic Diabetes Culture & Care NYC Public Health Research Articles

Key Finding: Hispanic diabetes data should be interpreted with culture, access, and community context in mind. Broad labels can hide meaningful differences, so prevention work should include screening, food access support, culturally aware education, primary care access, and heart-health prevention.

Source Articles

🌎

Understanding the Growing Epidemic of Type 2 Diabetes in the Hispanic Population Living in the United States

Summary

Explains how social, cultural, economic, biological, and health care access factors contribute to higher type 2 diabetes burden among Hispanic adults.

Open Article Research Page

🧭

Profiles of Social Determinants of Health and Change in Diabetes Status Among U.S. Hispanic/Latino Adults

Summary

Uses HCHS/SOL follow-up data to show how social adversity profiles are linked with worse diabetes status and worsening diabetes over time.

Open Article Research Page

🩺

The Prevalence of Type 1 Diabetes in Hispanic/Latino Populations in the United States

Summary

Uses HCHS/SOL data to estimate type 1 diabetes prevalence across Hispanic and Latino subgroups, separating the smaller type 1 diabetes story from the larger type 2 diabetes burden.

Open Article Research Page

📟

Navigating Continuous Glucose Monitoring Adoption

Summary

Explores barriers and facilitators to CGM adoption among Hispanic adults with insulin-treated type 2 diabetes through Spanish-language focus groups before and after 30 days of CGM use.

Open Article Research Page

📚 Hispanic Diabetes Source Library

A clean source shelf for the Hispanic diabetes evidence used in this section.

📄 Article Deep Dive

Type 1 diabetes prevalence evidence from the Hispanic Community Health Study/Study of Latinos.

The Prevalence of Type 1 Diabetes in Hispanic/Latino Populations in the United States: Findings from the Hispanic Community Health Study/Study of Latinos

Epidemiology, Kinney et al., 2020

This article adds an important type 1 diabetes layer to the Hispanic diabetes evidence story. It shows that type 1 diabetes is much less common than type 2 diabetes, but it still matters because people affected may have poor glycemic control and need targeted care.

JournalEpidemiology, 2020

Study DesignSecondary analysis of HCHS/SOL community-based epidemiologic data

Participants16,290 Hispanic/Latino adults, ages 18–74, with complete type 1 diabetes classification data

LocationsBronx, Chicago, Miami, and San Diego HCHS/SOL communities

Time Period2008–2011 baseline examination

Direct LinkEpidemiology / LWW source page

Open Article Research Page

Summary

This letter used HCHS/SOL baseline data to estimate type 1 diabetes prevalence among Hispanic and Latino adults from different backgrounds in the United States. The study used a type 1 diabetes definition based on diagnosis before age 30, current insulin treatment, and insulin use within one year of diagnosis. Among 16,290 adults with complete data, overall type 1 diabetes prevalence was 0.18%, or 1.8 per 1,000 persons. Dominican adults had the highest estimated prevalence at 0.61%, while Puerto Rican adults were estimated at 0.22%. The article also reported poor glycemic control among identified type 1 diabetes cases, with an overall average HbA1c of 9.62%. This article matters because it helps separate type 1 diabetes from the larger type 2 diabetes story while still showing that type 1 diabetes needs public health attention.

Objective

To estimate the prevalence of type 1 diabetes mellitus among diverse Hispanic and Latino background groups in the United States using HCHS/SOL data.

Main Variables

Type 1 diabetes status, Hispanic/Latino background, sex, current age group, age at diabetes diagnosis, current insulin treatment, insulin use within one year of diagnosis, and HbA1c.

Study Design

Secondary analysis of baseline HCHS/SOL data from a community-based epidemiologic study. The article is published as a research letter.

N/A Fields

Randomized trial: N/A. Case-control matching: N/A. Longitudinal follow-up for this type 1 analysis: N/A. Objective type 1 autoantibody testing: N/A.

Key Findings

Overall type 1 diabetes prevalence was 0.18%, or 1.8 per 1,000 persons.
Dominican adults had the highest estimated type 1 diabetes prevalence at 0.61%.
Puerto Rican adults had an estimated type 1 diabetes prevalence of 0.22%.
Overall average HbA1c among identified type 1 diabetes cases was 9.62%.
Average HbA1c ranged from 11.52% in Puerto Rican adults to 8.22% in Mexican adults.

Evidence note: Type 1 diabetes is rare compared with type 2 diabetes, but the high HbA1c values suggest that people identified with type 1 diabetes may still face serious control and care challenges.

🩺 Type 1 Diabetes Prevalence by Hispanic/Latino Background

What this means: Type 1 diabetes is rare overall, but the estimates vary by background, with the highest estimate among Dominican adults in this sample.

⚧ Type 1 Diabetes Prevalence by Sex

What this means: The overall male and female estimates were close, so this article does not suggest a large sex gap in type 1 prevalence.

📅 Type 1 Diabetes Prevalence by Current Age Group

What this means: The estimate was higher among adults younger than 30, which makes sense because type 1 diabetes often begins earlier in life.

🧪 Average HbA1c Among Identified Type 1 Diabetes Cases

What this means: HbA1c values were high, especially for Puerto Rican adults, which points to a need for better diabetes control support.

What This Means

This article supports the Hispanics dashboard because it separates type 1 diabetes from the broader type 2 diabetes burden. The professional takeaway is that type 1 diabetes is less common, but it should not disappear from public health storytelling. A complete diabetes dashboard should explain both the larger type 2 burden and the smaller group of people living with type 1 diabetes who may need insulin access, specialty care, and stronger glycemic control support.

📄 Article Deep Dive

Social determinants, adversity profiles, and diabetes status change in HCHS/SOL from 2008 to 2024.

Profiles of Social Determinants of Health and Change in Diabetes Status Among U.S. Hispanic/Latino Adults: HCHS/SOL, 2008–2024

Diabetes Care, Brown et al., 2026

This article gives the social roots part of the diabetes story a strong evidence base. It shows that social adversity does not happen one issue at a time. Income, education, employment, housing, language, stress, family cohesion, and social support can cluster together and shape diabetes risk over time.

JournalDiabetes Care, 2026

Study DesignProspective, population-based cohort study with latent class analysis

Participants16,415 Hispanic/Latino adults, ages 18–74; 16,371 included with available SDoH data

LocationsBronx, Chicago, Miami, and San Diego HCHS/SOL communities

Time PeriodBaseline 2008–2011; follow-up 2014–2017 and 2020–2024

Direct LinkDiabetes Journals source page

Open Article Research Page

Summary

This study examined how social determinants of health cluster together and how those patterns relate to diabetes status among Hispanic and Latino adults. The study used HCHS/SOL data from 2008 to 2024 and identified four social adversity profiles: low adversity, social/educational strengths, acculturated and underresourced, and high adversity. The high-adversity group had the highest diabetes burden at baseline and greater odds of worsening diabetes status over time. This article matters because it shows that diabetes prevention is not only about individual choices. It is also about income, education, work, housing, stress, language, family support, and social support.

Objective

To identify patterns of social adversity among U.S. Hispanic and Latino adults and examine how those profiles relate to diabetes status at baseline and changes in diabetes status across about 12 years.

Main Variables

Diabetes status, income, education, employment status, home ownership, language acculturation, social acculturation, chronic stress, family cohesion, social support, age, sex, Hispanic/Latino heritage, and field center.

Study Design

Prospective, population-based cohort study using HCHS/SOL data. The analysis used latent class analysis to identify social adversity profiles and ordinal regression models to test links with diabetes status.

N/A Fields

Randomized trial: N/A. Case-control matching: N/A. Direct intervention tested: N/A. Medication treatment comparison: N/A.

Key Findings

Four social adversity profiles were identified: low adversity, social/educational strengths, acculturated and underresourced, and high adversity.
The high-adversity group was the largest profile at about 39.70% of the sample.
At baseline, the high-adversity group had 21.86% diabetes, compared with 8.49% in the low-adversity group.
Compared with the low-adversity group, the high-adversity group had 51% higher odds of worse diabetes status at baseline.
The high-adversity group also had higher odds of worsening diabetes status at later follow-up visits.

Evidence note: This article strengthens the dashboard because it explains why diabetes disparities need both medical care and social support. The data point toward prevention that includes screening, food resources, language access, family support, and community referrals.

📊 HCHS/SOL Social Adversity Combo Chart — Profile Size + Diabetes Risk

What this means: This combo chart makes more sense than a map because the article is about social-adversity profiles, profile size, and diabetes-risk odds over time. The high-adversity group is both the largest profile and the strongest risk signal.

🧭 Social Adversity Profile Distribution

What this means: The high-adversity group was the largest profile, showing that social adversity was not a small side issue in this population.

🩺 Diabetes Status by Social Adversity Profile

What this means: Diabetes was highest in the high-adversity group, while normoglycemia was highest in the low-adversity group.

📈 Odds of Worse or Worsening Diabetes Status

What this means: The odds rise as adversity becomes more severe, which supports a dose-response style public health story.

🧩 Individual SDoH Signals at Baseline

What this means: Several social determinants were linked with diabetes status, but the article’s strongest point is that these conditions cluster together.

What This Means

This article supports the Hispanics dashboard because it explains why diabetes burden cannot be separated from people’s daily living conditions. For Hispanic and Latino communities, diabetes prevention should include culturally aware care, social support, stable access to health care, food and income support, language support, and trusted community-based outreach.

📄 Article Deep Dive

A review article explaining why type 2 diabetes is rising among Hispanic adults in the United States.

Understanding the Growing Epidemic of Type 2 Diabetes in the Hispanic Population Living in the United States

Diabetes/Metabolism Research and Reviews, Aguayo-Mazzucato et al., 2019

This article helps explain the bigger story behind the numbers. It connects diabetes risk to social conditions, culture, biology, obesity, access to care, complications, and culturally aware prevention.

JournalDiabetes/Metabolism Research and Reviews, 2019

Study DesignLiterature review / multidisciplinary review

ParticipantsN/A, review article

LocationsUnited States, Hispanic/Latino population focus

Time PeriodN/A, review of published literature

Direct LinkPubMed Central source page

Open Article Research Page

Summary

This review explains why type 2 diabetes is a growing problem among Hispanic adults living in the United States. It says the higher diabetes burden is not caused by one thing. It comes from a mix of social factors, cultural factors, biology, obesity, insulin resistance, access to health care, health literacy, food patterns, physical activity, and diabetes self-management support. The article also reviews diabetes complications and prevention programs, including culturally tailored education and lifestyle programs. This article matters because it gives the Hispanics page the “why” behind the charts. It explains how diabetes risk is shaped by daily life, not just personal choices.

Objective

To explain the growing type 2 diabetes burden among Hispanic adults in the United States using a multidisciplinary review of epidemiology, biology, social factors, complications, and prevention strategies.

Main Variables

Type 2 diabetes prevalence, obesity, insulin resistance, income, education, health insurance, acculturation, diet, physical activity, health literacy, cultural beliefs, diabetes complications, and prevention programs.

Key Findings

Hispanic adults in the United States have higher type 2 diabetes prevalence and incidence than the national average.
The review connects higher risk to lower income, lower access to education and health care, obesity, insulin resistance, and cultural and social conditions.
HCHS/SOL findings reviewed in the article show about 18% diabetes prevalence for Puerto Rican, Dominican, Mexican, and Central American adults.
Obesity is described as a major modifiable risk factor, and BMI is linked with higher diabetes prevalence.
Diabetes self-management education, lifestyle change, metformin, and culturally tailored programs are described as important prevention and management tools.

🧬 Conceptual Model of Type 2 Diabetes Risk

What this means: This recreated figure shows that type 2 diabetes does not come from one single cause. Genetic risk, social conditions, environmental exposures, and metabolic changes work together, which supports the article’s core message that diabetes is shaped by systems, not just individual behavior.

📈 Diabetes Mortality Trends Over Time

Death Rate Trends Over Time

What this means: This recreated line chart shows diabetes rising as a major cause of death over time. The bigger height gives the labels, legend, and trend lines more room so the chart is easier to read.

📊 2014 Diabetes Mellitus Death Rates

2014 Diabetes Mellitus Death Rates

What this means: This recreated bar chart shows that some Hispanic and Latin American populations carry a much heavier diabetes mortality burden than others. That supports the article’s point that diabetes risk is unequal and connected to community conditions.

What This Means

This article supports the Hispanics dashboard because it explains the larger diabetes ecosystem around Hispanic and Latino communities. It shows that diabetes prevention should include more than telling people to “eat better.” Stronger prevention needs culturally aware education, affordable care, food access, family support, safe places to be active, language access, health literacy, and trusted community programs.

📄 Article Deep Dive

Technology access, trust, language, cost, and real-world CGM use among Hispanic adults with insulin-treated type 2 diabetes.

Navigating Continuous Glucose Monitoring Adoption: Insights From Hispanic Adults With Insulin-Treated Type 2 Diabetes

Journal of Diabetes Research, Soliman et al., 2026

This article adds a technology equity chapter to the Hispanic diabetes story. It shows that CGM adoption is not just about whether a device exists. It also depends on cost, insurance, language access, provider guidance, peer examples, and whether people feel supported using the technology.

JournalJournal of Diabetes Research, 2026

Study DesignQualitative pilot study using Spanish-language focus groups

Participants16 Hispanic adults with insulin-treated type 2 diabetes

LocationsUniversity of Miami, Miami, Florida

Time PeriodRecruitment from Dec. 2023 to Feb. 2024, focus groups from winter 2023 to spring 2024

Direct LinkPubMed Central source page

Open Article Research Page

Summary

This study explored why Hispanic adults with insulin-treated type 2 diabetes may or may not adopt continuous glucose monitoring, also called CGM. Researchers held Spanish-language focus groups at the University of Miami with 16 Hispanic adults who had type 2 diabetes, used insulin, had HbA1c of at least 8%, and had not used CGM in the past 2 years. Participants first discussed barriers to starting CGM, then used real-time CGM for 30 days, then returned for a second focus group. The study found that major barriers included device cost, insurance coverage, alarm fatigue, limited culturally matched provider guidance, and lack of Spanish-language support. After using CGM, many participants reported better food awareness, better glucose control, fewer fingersticks, and a strong desire to keep using the device.

Objective

To identify societal, policy, interpersonal, community, and individual barriers and facilitators that affect CGM access and adoption among Hispanic adults with insulin-treated type 2 diabetes.

Main Variables

CGM access, CGM adoption, insurance coverage, device cost, alarm fatigue, Spanish-language support, provider guidance, peer modeling, diabetes knowledge, diet awareness, glycemic control, fingerstick burden, HbA1c, and CGM uptake after the study.

Key Findings

The study included 16 Hispanic adults with insulin-treated type 2 diabetes. Mean age was 59.68 years, and baseline HbA1c was 9.78.
Major barriers included high device costs, limited insurance coverage, alarm fatigue, lack of Spanish-language instructions, and limited culturally concordant provider guidance.
Facilitators included manufacturer discounts, peer modeling, caregiving support, real-time glucose feedback, and the desire to avoid fingerstick testing.
After the 30-day CGM trial, most participants described CGM as useful for food awareness, safety alerts, glucose control, and daily diabetes decisions.
By the 8-week follow-up, 11 of 16 participants had independently obtained a CGM through their provider and insurance benefits.

📟 Pre-CGM Barriers and Facilitators by SEM Level

What this means: CGM access problems happen at more than one level. Cost and insurance matter, but so do community exposure, provider guidance, language access, and patient confidence.

✨ Benefits Discussed After 30 Days of CGM Use

What this means: Once participants actually tried CGM, they saw practical benefits. The strongest themes were low-blood-sugar alerts and food awareness, which connect directly to daily self-management.

✅ CGM Uptake at 8-Week Follow-Up

What this means: Most participants wanted CGM enough to continue after the trial. The issue was not lack of interest. The bigger issue was access.

📈 CGM Access Pathway Over Time

What this means: This line-style chart shows the movement from no recent CGM use, to the 30-day trial, to 11 of 16 participants obtaining CGM by follow-up.

👥 Participant Snapshot

What this means: This was a small pilot group, but it focused on people with real clinical need: insulin-treated type 2 diabetes, high HbA1c, and no recent CGM use.

What This Means

This article supports the Hispanics dashboard because it moves the story from diabetes burden to diabetes tools. It shows that technology can help, but only when people can access it, understand it, afford it, and get support in their language and culture. For Hispanic adults using insulin, CGM can turn blood sugar data into daily feedback, but health systems must remove cost, insurance, language, and provider-education barriers.

🛠️

Interactive Tools

Reusable Analytics Utilities

Charts / Maps / Data Cleaning

📊

Pivot Table Explorer

Drag-and-drop pivot table powered by PivotTable.js. Slice diabetes indicators by borough, year, race, age group, and payor type. Export to CSV or Excel.

Launch Tool 🌿

🔗

Correlation Explorer

Scatter plot tool to explore correlations between diabetes prevalence and social determinants: poverty rate, food access score, insurance coverage, and PCP density.

Launch Tool 🌿

🗺️

Map Overlay Builder

Layer multiple diabetes indicators onto an interactive NYC map. Toggle between prevalence, A1C rates, amputations, and dialysis cases by neighborhood.

Launch Tool 🌿

🧹

Data Cleaning Scripts

Documented Python and R scripts used to clean, normalize, and validate the EHDP and SPARCS datasets. Includes column standardization, missing value handling, and date parsing.

View Scripts 🌿

📈

Chart Template Builder

Generate forest-themed Chart.js charts for any diabetes indicator. Choose chart type, color palette, and export as PNG or embed-ready JavaScript.

Launch Tool 🌿

🔍

Dataset Slicer

Filter and slice the full NYC EHDP diabetes dataset by any combination of borough, year, age group, race/ethnicity, and sex. Download filtered results as CSV.

Launch Tool 🌿

📚

Reference & Data Sources

Datasets, Definitions, and Methods

Sources / Links / Attribution

🌐 Primary Data Sources

NYC Environment & Health Data Portal (EHDP)

github.com/nychealth/EHDP-data

Borough-level and neighborhood-level diabetes indicators including prevalence, A1C control, amputations, and dialysis. JSON format, organized by IndicatorID.

NYC DOHMH Indicator Explorer — Chronic Disease (Diabetes)

a816-dohbesp.nyc.gov/IndicatorPublic/data-explorer/chronic-disease/?id=2465

Direct link to the NYC Environment & Health Data Portal chronic disease explorer, pre-loaded with all four diabetes indicators: Adults with Diabetes, A1C > 9% (very high blood sugar), Lower Extremity Amputations (diabetes-related), and Dialysis Patients (diabetes-related). Includes maps, trend charts, borough and neighborhood breakdowns, and correlation views by poverty level.

🏥 2024 SPARCS Data — Diabetes · NYC 5 Boroughs · By Age Group

Hospital inpatient discharges filtered to diabetes CCSR diagnoses, NYC hospital counties, discharge year 2024. Each link opens directly in NY State Open Data pre-filtered to that age group.

Diabetes Without Complication Diabetes With Complication Prediabetes Maternal Diabetes NYC 5 Boroughs · sf4k-39ay

👶

0 to 17 — Pediatric

Open Dataset ↗

🧑

18 to 29 — Young Adult

Open Dataset ↗

🧍

30 to 49 — Adult

Open Dataset ↗

🧓

50 to 69 — Middle-Older Adult

Open Dataset ↗

👴

70 or Older — Elderly

Open Dataset ↗

🏥 2023 SPARCS Data — Diabetes · NYC 5 Boroughs · By Age Group

Same four diabetes CCSR categories, NYC boroughs, discharge year 2023. Note: 2023 uses 3-digit zip and hospital_service_area field — Manhattan coded as "Manhattan" (vs "New York" in 2024).

Diabetes Without Complication Diabetes With Complication Prediabetes Maternal Diabetes NYC 5 Boroughs · 46xm-urtu · 3-digit zip

👶

0 to 17 — Pediatric

Open Dataset ↗

🧑

18 to 29 — Young Adult

Open Dataset ↗

🧍

30 to 49 — Adult

Open Dataset ↗

🧓

50 to 69 — Middle-Older Adult

Open Dataset ↗

👴

70 or Older — Elderly

Open Dataset ↗

NYSDOH SPARCS De-Identified Overview 2024

NYSDOH_SPARCS_De-Identified_Overview_2024.pdf (Download)

Official NY State DOH overview document for the 2024 SPARCS de-identified inpatient dataset (sf4k-39ay). Describes the scope, methodology, data collection process, suppression rules, and intended use of the discharge-level hospital data. Essential companion document for understanding how SPARCS data is structured and how to interpret its fields correctly.

NYSDOH SPARCS De-Identified Data Dictionary 2024

NYSDOH_SPARCS_De-Identified_Data_Dictionary_2024.pdf (Download)

Complete field-by-field data dictionary for the 2024 SPARCS de-identified dataset. Defines every column including APR-DRG codes, CCSR diagnosis and procedure codes, severity of illness levels, risk of mortality categories, payment typology values, and all demographic fields. Required reference for any analysis using the SPARCS Endocrine inpatient discharge data.

AHRQ Quality Indicators (QI) — Indicators List v2023

qualityindicators.ahrq.gov — AHRQ QI Indicators List (PDF)

Agency for Healthcare Research and Quality (AHRQ) standardized quality measures used with SPARCS and other hospital discharge data. Covers four indicator modules: Prevention Quality Indicators (PQI), Inpatient Quality Indicators (IQI), Patient Safety Indicators (PSI), and Pediatric Quality Indicators (PDI). Published October 2023, AHRQ Pub. No. 24-0007.

🩸 Diabetes-Relevant Indicators:

PQI 01 — Diabetes Short-Term Complications PQI 03 — Diabetes Long-Term Complications PQI 14 — Uncontrolled Diabetes Admission Rate PQI 16 — Lower-Extremity Amputation (Diabetes) PQI 93 — Prevention Quality Diabetes Composite PDI 15 — Pediatric Diabetes Short-Term Complications

🗺️ UHF Neighborhood Code Reference

nyc.gov/assets/doh/downloads/pdf/ah/zipcodetable.pdf

42 neighborhoods · 5 boroughs · with UHF code, neighborhood name, and zip codes · Source: NYC DOHMH & United Hospital Fund

👶 SPARCS — Pediatric Prevention Quality Indicators (PDI) by Patient County · NYC · Beginning 2009

health.data.ny.gov — SPARCS PDI by County (vh2s-8wb2) · Filtered to NYC · Diabetes

Hospital inpatient discharge data measuring Pediatric Prevention Quality Indicators (PDI) for all five NYC counties — Bronx, New York (Manhattan), Kings (Brooklyn), Queens, and Richmond (Staten Island) — filtered to diabetes, beginning 2009. Reports observed rate, expected rate, risk-adjusted rate, and difference in rates per 100,000 people by discharge year and PDI number. Directly relevant to AHRQ PDI 15 (Pediatric Diabetes Short-Term Complications Admission Rate).

PDI 15 — Pediatric Diabetes Short-Term Complications All 5 NYC Counties Risk-Adjusted Rates Beginning 2009

📖 Key Definitions

A1C (HbA1c)

A blood test measuring average blood glucose over the prior 2 to 3 months. A1C greater than 9% indicates poor glycemic control and is associated with significantly higher risk of diabetes complications.

Diabetes Prevalence

The percentage of the adult population (age 18 and older) who report being told by a healthcare provider that they have diabetes. Measured via NYC Community Health Survey.

SPARCS

Statewide Planning and Research Cooperative System. Collects patient-level detail on every hospital inpatient discharge in New York State, including diagnosis, procedure, cost, and payment information. This hub uses the 2024 de-identified dataset filtered to Endocrine diagnoses (dataset ID: sf4k-39ay) for diabetes hospitalization analysis.

EHDP

Environment and Health Data Portal, maintained by NYC DOHMH. Provides hundreds of indicators on how environmental and social conditions shape health outcomes across NYC neighborhoods.

📚 Research Literature — Peer-Reviewed Sources

The Prevalence of Type 1 Diabetes in Hispanic/Latino Populations

journals.lww.com — Epidemiology Journal · 2020

Dominicans have the highest Type 1 prevalence of all Hispanic subgroups at 6.1 per 1,000. Among Puerto Ricans with Type 1, average A1C was 11.52 — severely uncontrolled. Critical evidence for the misdiagnosis crisis in Caribbean communities.

Dominican Type 1: 6.1/1,000 Puerto Rican A1C: 11.52 Epidemiology Journal · 2020

Understanding the Growing Epidemic of Type 2 Diabetes in the Hispanic Population

pmc.ncbi.nlm.nih.gov — PMC/NIH · Free Full Text

Diagnosed diabetes projected to increase 198% overall by 2050 — but 481% for Hispanic populations, more than double the national rate. Puerto Ricans and Dominicans at the highest current burden will drive this disproportionately.

481% Hispanic Projection vs 198% Overall PMC/NIH · Free Full Text

Profiles of Social Determinants of Health and Change in Diabetes Status — HCHS/SOL 2008–2024

diabetesjournals.org — Diabetes Care, ADA · 2025

High-adversity profile had 51% greater odds of worse diabetes status at baseline and 32% greater odds of worsening 12 years later. Acculturation stress, limited education, low income, and psychosocial burden compound into a trajectory that medication alone cannot address.

51% Greater Odds Baseline 32% Worse at 12 Years HCHS/SOL 2008–2024

👩🏾

Jasmine V.

About the Creator

Health Services Administration

🌿 Bio & Mission

I'm a returning adult student at Lehman College pursuing dual degrees in Health Services Administration and Business Administration with a focus on Human Resource Management. My career goal is data analytics, with a focus on healthcare data — cleaning, analyzing, and visualizing information that can drive real public health decisions.

This portfolio focuses on diabetes because it is one of the most prevalent and preventable chronic conditions disproportionately affecting New York City's most vulnerable communities. I built this hub to bridge the gap between raw government data and accessible, actionable insight.

The forest theme reflects my belief that good data work should feel grounding — calm, clear, and rooted in something real.

🛠️ Skills & Tools

Excel Tableau R Jamovi Python SQL HTML/CSS Chart.js Data Cleaning SPARCS Analysis Public Health Analytics APA Writing Epidemiology Managed Care

📚 Coursework Highlights

📊 HSA 312 — Managed Health Care
🏥 HSA 267 — Management of Healthcare Organizations
🇺🇸 HSD 266 — US Health Care System
🔬 HSD 269 — Epidemiology & Biostatistics
💻 Computer Information Systems Minor

📬 Contact

Open to internship and entry-level data analyst opportunities in healthcare.

💊

Prescription Drug Data

Diabetes Medications

NYS Pharmacy Records

Payer Type

Sort By

Loading...

14.1M

Total Diabetes Prescriptions (2023)

↑ All 3 payer types combined

$5.0B

Total Amount Paid (2022)

↑ Insurer + member combined

Medicare

Largest Payer by Prescriptions

↑ 7.4M Rx (52% of total)

Metformin

Most Prescribed Diabetes Drug

↑ 4.88M Rx across all payers

💊 Top 10 Diabetes Drugs by Prescriptions

💰 Total Paid by Payer Type

Fetching live data from NY State Open Data API...

📰

Diabetes News & Breakthroughs

Latest Diabetes Updates

Research / Medications / Care

Fetching latest diabetes news...

🔥 Featured

GLP-1 Revolution: Semaglutide & Tirzepatide Transform Diabetes Care

GLP-1 receptor agonists like semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) have fundamentally changed how Type 2 diabetes is managed. In New York State alone, semaglutide accounted for over 731,000 prescriptions in 2022 — generating $761 million in total payments. These drugs not only lower blood sugar but reduce cardiovascular risk and promote significant weight loss, leading major guidelines to recommend them earlier in treatment pathways.

GLP-1 Agonists Cardiovascular Benefit Weight Loss

💉

Medication

Tirzepatide Approved for Type 2 Diabetes & Obesity

Eli Lilly's tirzepatide (Mounjaro for diabetes, Zepbound for obesity) targets both GLP-1 and GIP receptors — a dual mechanism that produces greater A1C reductions than single-agonist drugs. Clinical trials showed A1C drops of up to 2.3% and weight loss averaging 15-22% of body weight.

Dual Agonist FDA Approved

🧬

Research

SGLT2 Inhibitors Show Kidney Protection Benefits

Empagliflozin and dapagliflozin (SGLT2 inhibitors) have demonstrated significant kidney-protective effects beyond blood sugar control. In NY State 2023 data, empagliflozin had 1.05M+ prescriptions totaling $1.09B — reflecting rapid adoption driven by new cardiovascular and renal outcome trial data.

SGLT2 Kidney Health

📊

Cost Crisis

Insulin Affordability: NY State Caps & Federal Action

Insulin glargine remains the second most prescribed diabetes drug in NY (1.13 million Rx, $441M total paid in 2022). New York's insulin cost-sharing cap of $100/month and the federal Inflation Reduction Act's $35 Medicare cap are beginning to reduce out-of-pocket burdens for patients.

Policy Affordability

🤖

Technology

Closed-Loop Insulin Systems (Artificial Pancreas)

Hybrid closed-loop systems that automatically adjust insulin delivery using continuous glucose monitor readings have received expanded FDA clearance. These systems dramatically reduce hypoglycemia risk and improve time-in-range metrics, particularly for Type 1 diabetes patients.

CGM Type 1

🏥

NYC Focus

NYC Health + Hospitals Expands Diabetes Prevention

NYC's public hospital system has expanded the National Diabetes Prevention Program (DPP) at all 11 facilities. Targeting neighborhoods with the highest Bronx and Brooklyn diabetes rates, the program offers lifestyle coaching to prevent progression from prediabetes to Type 2 diabetes.

Prevention NYC

🔬

Pipeline

Oral GLP-1s & Once-Weekly Insulin in Development

Oral semaglutide (Rybelsus) is already available; once-weekly insulin icodec received FDA approval in 2024. Multiple oral GLP-1 candidates are in Phase 3 trials that could dramatically improve adherence by eliminating injections for millions of patients with Type 2 diabetes.

Pipeline Oral GLP-1

⭐

Diabetic Recommended

Evidence-Based Resources

Apps / Tools / Lifestyle

💊 Recommended Medication Classes

Based on ADA Standards of Care 2024 and NY State prescribing data. Always consult your healthcare provider.

Metformin — First-Line Standard

Most prescribed diabetes drug in NY State (4.88M Rx in 2022). Affordable, effective, and well-tolerated. Reduces hepatic glucose production. Recommended as first-line therapy by ADA for Type 2 diabetes unless contraindicated.

First-Line Generic Available $84M Total Paid (NY 2022)

GLP-1 Receptor Agonists

Semaglutide and dulaglutide are among the top 5 most prescribed diabetes drugs in NY State. These medications reduce A1C, promote weight loss, and offer proven cardiovascular benefits. ADA now recommends them early in treatment, especially for patients with heart or kidney disease.

Cardiovascular Benefit Weight Loss 731K+ Rx in NY 2022

SGLT2 Inhibitors

Empagliflozin, dapagliflozin, and canagliflozin reduce blood sugar by removing glucose through urine. Strong evidence for heart failure prevention and kidney protection. 725K+ empagliflozin prescriptions in NY in 2022 reflect growing clinical adoption.

Kidney Protective Heart Failure Benefit $609M NY 2022

Insulin Therapy

Insulin glargine is the second most prescribed diabetes drug in NY (1.13M Rx, $441M). Long-acting insulin remains essential for Type 1 diabetes and many Type 2 patients. Newer formulations offer once-weekly dosing (icodec) and faster action profiles.

Essential for Type 1 Basal Insulin $35 Medicare Cap

📱 Recommended Monitoring Tools

Continuous Glucose Monitors (CGM)

✅ Dexcom G7 — 10-day wear, real-time alerts, no fingersticks
✅ Abbott FreeStyle Libre 3 — smallest CGM sensor, 14-day wear
✅ Medtronic Guardian 4 — integrates with closed-loop pump systems

ADA Recommended

Top Diabetes Management Apps

✅ MySugr — logbook, A1C estimator, coaching
✅ One Drop — AI-powered glucose predictions
✅ Glooko — syncs with CGM and glucose meters
✅ Noom for Diabetes — behavior-based coaching

Free & Paid Options

Nutrition Resources

✅ ADA Diabetes Food Hub — diabetesfoodhub.org
✅ Carb Manager — carb tracking and meal planning
✅ Cronometer — micronutrient tracking
✅ Plate Method — half vegetables, quarter protein, quarter carbs

Evidence-Based

🗽 NYC-Specific Resources

NYC Health + Hospitals — Diabetes Prevention Program

nychealthandhospitals.org

Free lifestyle change program at all 11 NYC public hospitals. Targets prediabetes. Available in Spanish, Chinese, and other languages.

DOHMH Diabetes Prevention & Control

nyc.gov/health

Borough-specific diabetes programs, A1C testing events, and community health worker programs in high-burden neighborhoods.

Medicaid Coverage — NY State

health.ny.gov/medicaid

NY Medicaid covers CGMs, diabetes supplies, and most diabetes medications. NYS Programs accounted for 4.7M prescriptions in 2022 alone.

💬

Community Blog & Forum

Personal Notes and Shared Learning

Diabetes / Public Health

✍️ Share Your Thoughts

Filter by Category

4 posts

🏥

2024 SPARCS Data

Diabetes · NYC Hospital Data

NYC 5 Boroughs / Age Groups

Age Group: Open in SPARCS ↗

📊 Currently viewing: 0–17 · Pediatric · 639 discharges · NYC 2024

639

Total Discharges

↑ NYC 5 Boroughs · 2024

3.0

Avg Length of Stay (days)

↑ Median 2.0 days

$56,335

Mean Total Charges

↑ Median $40,993

65%

Medicaid Share

↑ 415 of 639 discharges

81%

Emergency Admissions

↑ 558 of 639 discharges

98%

Diabetes With Complication

↑ 628 of 639 discharges

🔍 Key Finding: 98% of pediatric diabetes hospitalizations in NYC (2024) involved complications — suggesting children are often not reaching care until their diabetes is already serious. 87% arrived through the Emergency Department rather than planned admissions.

🏙️ Discharges by Borough

💰 Payer Mix

⚕️ Severity of Illness

🌡️ Risk of Mortality

🧬 Race

🌎 Ethnicity

💵 Avg Charges by Borough

🚑 Type of Admission

🏨 Top Facilities by Discharges

📉 Length of Stay vs Avg Charges by Borough

📋 Borough Summary Table

Borough	Discharges	Avg Length of Stay	Avg Total Charges	Total Charges

Turning Diabetes DataInto Action

🌲 Why This Hub?

🌱 Key Focus Areas

Diabetes Analytics Dashboard

🌿 Dashboard Slicers

📊 Diabetes Inpatient Discharges — All NYC Boroughs (26,147)

📈 2024 Diabetes Discharges by Age Group

🏥 Avg Length of Stay by Borough (days)

🚨 Emergency Department Share % by Borough

🧬 2024 Diabetes Discharges by Race/Ethnicity (Patient Count)

💵 2024 Total Inpatient Charges vs Costs by Borough (Diabetes, NYC)

📋 Borough Comparison Table

Research Articles

2022 : Renal disease in patients with type 2 diabetes: Magnitude of the problem, risk factors and preventive strategies

2025 : Diabetes and Health Inequities among New York City Adults

SPARCS Long/Short Term Complications and Amputations

2024 : Patients with diabetes struggling to afford food and control their HbA1c in food-insecure areas in Bronx, NY

2022 : New York State Diabetes-Related Amputation: A Horror Story

2024 : Diabetes Incidence and Prevalence

2025 : Epidemiological Patterns of Diabetes Mellitus in The United States of America: An Observational Multicenter Analysis From 1990 to 2024

2025 : Navigating Continuous Glucose Monitoring Adoption: Insights From Hispanic Adults With Insulin-Treated Type 2 Diabetes

Renal Disease in Type 2 Diabetes — Magnitude, Risk Factors & Prevention

📊 Diabetes and DKD Burden

🌎 Global Diabetes Growth, 2021 to 2045

💵 Diabetes Health Expenditure Forecast

🛡️ Prevention and Kidney-Protection Signals

🧬 DKD Clinical Progression Pathway

Diabetes & Health Inequities Among NYC Adults — EPI Data Brief No. 146

Key Findings — Tables 1, 3 & 5

🏙️ Chart 1 · Diabetes Prevalence by Borough — 2022 (Table 1)

🧬 Chart 2 · Diabetes Prevalence by Race/Ethnicity — 2022 (Table 1)

💰 Chart 3 · Diabetes Prevalence by Neighborhood Poverty (Table 1)

📅 Chart 4 · Diabetes Prevalence by Age Group (Table 1)

🧪 Chart 5 · A1C Blood Sugar Control by Borough — 2022 (Table 3) · % of patients in each A1C range

🦵 Chart 6 · Amputation Rate by Borough per 100K — 2022 (Table 5)

🧬 Chart 7 · Amputation Rate by Race/Ethnicity per 100K (Table 5)

💰 Chart 8 · Amputation Rate by Neighborhood Poverty (Table 5)

⚧ Chart 9 · Amputation Rate by Sex per 100K (Table 5)

Food Insecurity & Poor A1C Control in the Bronx — Bronx, NY Study

Charts and Data Tables

📄 Research Article & Data — Food Insecurity

Key Findings — Tables 1, 2 & 3

📊 Chart 1 · Poor A1C by Race/Ethnicity (Table 1)

📊 Chart 2 · Poor A1C by Insurance Type (Table 1)

📊 Chart 3 · Adjusted Odds Ratios — Food Need Groups (Table 3)

📊 Chart 4 · Poor A1C by Age Group (Table 1)

📊 Chart 5 · Bivariate vs Adjusted Odds Ratios (Tables 2 & 3)

📊 Chart 6 · % with Poor A1C by Food Need × Neighborhood (Table 1)

New York State Diabetes-Related Amputation: A Horror Story

📈 Diabetes-Related Amputation Rate Trends — NYC Boroughs + NY State

🏙️ 2009–2017 Increase Comparison

🧮 Documented vs Projected Amputations

⚠️ Five-Year Death Rate After Amputation

🦶 Prevention Impact Examples

What This Means

📊 Research Article & Data

SPARCS PQI Data — Diabetes Indicators · NYC 2009–2023

🦵 Amputation Rate by Borough — 2023

🏙️ All PQI Indicators by Borough — 2023

📅 Bronx Amputation Trend 2009–2023

📈 Amputation Trend All Boroughs 2009–2023

Hispanic Diabetes: Data, Culture, and Care

Hispanics

Source Articles

Understanding the Growing Epidemic of Type 2 Diabetes in the Hispanic Population Living in the United States

Profiles of Social Determinants of Health and Change in Diabetes Status Among U.S. Hispanic/Latino Adults

The Prevalence of Type 1 Diabetes in Hispanic/Latino Populations in the United States

Navigating Continuous Glucose Monitoring Adoption

📚 Hispanic Diabetes Source Library

📄 Article Deep Dive

The Prevalence of Type 1 Diabetes in Hispanic/Latino Populations in the United States: Findings from the Hispanic Community Health Study/Study of Latinos

Summary

Objective

Main Variables

Study Design

N/A Fields

Key Findings

🩺 Type 1 Diabetes Prevalence by Hispanic/Latino Background

⚧ Type 1 Diabetes Prevalence by Sex

📅 Type 1 Diabetes Prevalence by Current Age Group

Turning Diabetes Data
Into Action